ABSTRACT
Introducción: La toracoplastia percutánea videoasistida implica un acceso quirúrgico complejo y con riesgo de dañar estructuras vitales durante el procedimiento. Históricamente se han aplicado distintos sistemas de tracción y elevación esternal durante la intervención con el fin de minimizar el riesgo asociado al paso del instrumental entre el esternón y el pericardio. Métodos: Se presenta mediante una descripción ilustrada un nuevo sistema de tracción esternal. Se extrajeron los datos clínicos y sociodemográficos de los 36 pacientes intervenidos en nuestro centro de Pectus Excavatum entre julio 2017 y agosto 2021. Todos los pacientes fueron intervenidos por el mismo cirujano. Se clasificó a los pacientes en función de si se había empleado el sistema de tracción esternal (TE) o no (ST). La asignación a uno u otro grupo de intervención se hizo siguiendo un criterio cronológico, sin aplicar el índice de Haller u otro índice. El análisis estadístico de los datos recogidos se realizó con STATA, versión 15.0 (StataCorp). Resultados: La distribución de las variables sociodemográficas muestra que no había diferencias significativas entre los grupos. En 25 de los pacientes se empleó el sistema TE y en 11 no se utilizó ningún ST. El Índice de Haller fue de 4,19±0,7 para el grupo TE y de 3,79±0,3 para el ST. El tiempo quirúrgico medio en minutos fue 88,13±18,1 para el grupo TE y 97,73±46,2 para el grupo ST (p=0,87). La media de días de ingreso fue 7,67±0,8 y 7,73±1,3 para el grupo TE y ST respectivamente. La media de días de PCA intravenosa fue 6,08±0,7 para el grupo TE y 5,89±1,5 para el ST. La media de días de PCA epidural fue 3,79±0,5 y de 3,36±0,5 para el grupo TE y ST respectivamente (p=0,01). Todos los pacientes presentaron una evolución postoperatoria favorable. Ninguno de los pacientes presentó molestias a nivel de las heridas esternales durante el ingreso en hospitalización. La evolución cosmética fue favorable en todos los pacientes. (AU)
Introduction: Video-assisted percutaneous thoracoplasty involves a complex surgical access with risk of damaging vital structures during the procedure. Historically, different traction and sternal elevation systems have been applied during the intervention to minimize the risk associated with the passage of the instruments between the sternum and the pericardium. Methods: A new sternal traction system is presented by means of an illustrated description. Clinical and sociodemographic data were extracted from the 36 patients operated in our center for Pectus Excavatum between July 2017 and August 2021. The Haller index was not applied as a criterion to determine the use or not of the sternal traction system. Patients were classified according to whether the sternal traction system (TE) or not (ST) had been employed. Statistical analysis of the data collected was performed with STATA, version 15.0 (StataCorp). Results: Both groups were comparable. In 25 of the patients the described traction system was used, and in 11 no traction system was used. Haller's index was 4.19±0.7 for the TE group and 3.79±0.3 for the ST group. All patients were operated on by the same surgeon. The mean operative time in minutes was 97.73±46.2 for the ST group and 88.13±18.1 for the TE group (P=.87). The mean total days of admission was 7.67±0.82 (TE) and 7.73±1.35 (ST). Mean days of intravenous PCA was 6.08±0.72 (TE) and 5.89±1.45 (ST). The mean number of epidural PCA days was 3.79±0.5 (TE) and 3.36±0.5 (ST) (P=.01). All patients presented a favorable postoperative evolution. None of the patients presented discomfort at the level of the sternal wounds during hospitalization. Cosmetic evolution was favorable in all patients. (AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Thoracoplasty/adverse effects , Sternum/surgery , Funnel Chest/surgery , Traction , Video-Assisted SurgeryABSTRACT
INTRODUCTION: Video-assisted percutaneous thoracoplasty involves a complex surgical access with risk of damaging vital structures during the procedure. Historically, different traction and sternal elevation systems have been applied during the intervention to minimize the risk associated with the passage of the instruments between the sternum and the pericardium. MATERIAL AND METHODS: A new sternal traction system is presented by means of an illustrated description. Clinical and sociodemographic data were extracted from the 36 patients operated in our center for Pectus Excavatum between July 2017 and August 2021. The Haller index was not applied as a criterion to determine the use or not of the sternal traction system. Patients were classified according to whether the sternal traction system (TE) or not (ST) had been employed. Statistical analysis of the data collected was performed with STATA, version 15.0 (StataCorp). RESULTS: Both groups were comparable. Haller's Index was 4.19 ± 0.7 for the sternal traction (TE) group and 3.79 ± 0.3 for the no sternal traction (ST) group. In 25 of the patients the described traction system was used, and in 11 no traction system was used. All patients were operated on by the same surgeon. The mean operative time in minutes was 97.73 ± 46.2 for the ST group and 88.13 ± 18.1 for the TE group (p = 0.87). The mean total days of admission was 7.67 ± 0.82 (TE) and 7.73 ± 1.35 (ST). Mean days of intravenous PCA was 6.08 ± 0.72 (TE) and 5.89 ± 1.45 (ST). The mean number of epidural PCA days was 3.79 ± 0.5 (TE) and 3.36 ± 0.5 (ST) (p = 0.01). All patients presented a favorable postoperative evolution. None of the patients presented discomfort at the level of the sternal wounds during hospitalization. Cosmetic evolution was favorable in all patients. CONCLUSIONS: The sternal traction system presented provides safety when performing retrosternal dissection and placement of the thoracoplasty bar, leading to a decrease in surgical time in cases with a Haller Index higher than 3.5. There have been no complications associated with its use, nor has there been an increase in the number of days of hospitalization or analgesic requirements. There are no aesthetic sequelae for the patients.
Subject(s)
Funnel Chest , Thoracoplasty , Humans , Thoracoplasty/methods , Sternum/surgery , Funnel Chest/surgery , Funnel Chest/complications , Minimally Invasive Surgical Procedures/methods , HospitalizationABSTRACT
BACKGROUND: We previously developed a novel technique for expanding highly activated and purified natural killer (NK) cells able to maximize the theoretical activation potential of NK cells; thus, we named this cell population zenithal-NK (ZNK). AIM: To evaluate the safety, feasibility, and preliminary efficacy of autologous ZNK cells in patients with different types of advanced cancer with measurable solid lesions. PATIENTS AND METHODS: In this phase I/IIb first-in-human, open-label, dose-escalation study (trial registration ID: UMIN-000011555), eligible patients received ZNK cells intravenously starting from 106 to 108 cells/patient/dose at 2-week dosing intervals. A maximum of six cycles were allowed. Safety and survival analyses were also carried out for cases that were excluded and never administered ZNK cells. RESULTS: As of April 20, 2017, a total of nine patients were enrolled in this study, with one recruited twice. Overall, neither grade 2 or higher toxicities (Common Terminology Criteria for Adverse Events v5.0) caused by cell administration, nor adverse events causing discontinuation of protocol treatment were found. In four cases, the number of administered ZNK cells was increased to 108 cells/body/dose without any serious dose-limiting toxicity; the maximally tolerated dose was therefore considered to be at least 108 cells. The overall response rate was 40.0% in 10 net cases, one of partial response and three of stable disease, and the patient with partial response is still alive after 4 year's observation. CONCLUSION: These results demonstrate that autologous ZNK cells are safe and well-tolerated in patients with different types of advanced solid tumors. Clinical studies using similarly active ZNK cells from human leukocyte antigen/killer cell immunoglobulin-like receptor-mismatched healthy donors under Good Manufacturing Practice-compliant manufacturing, and with modified treatment regimen, i.e. doses and frequencies, are warranted for further investigation to show the potential of ZNK cells in such patients.
